Skip to content
Catalyst brief · Phase 3 readout · 12 days

Tradipitant: Tradipitant in Nausea and Vomiting

Vanda Pharmaceuticals · $VNDA · built 19 Nov 2026 from 17 sourced facts · open on the radar

Analyst desk

Five AI analysts read the facts below. Each sentence shows the facts it rests on.

Trial design

  • The trial's quadruple blind design and randomised allocation will help to reduce bias and increase the reliability of the results, which will be based on the proportion of participants with at least 1 vomiting episode per week in the tradipitant group compared to the placebo group. F3 F4 F5
  • The trial's relatively small size of 280 patients may limit the precision of the results, but the use of a daily symptom diary to measure the main goal will provide detailed data on the participants' symptoms. F2 F3 F6

Base rates

  • The historical success rate of Phase 3 programmes in the relevant group is 62.1%, which is an industry average and not a forecast for this trial. F12
  • VNDA has a record of keeping dates, with only 8% of their active Phase 2 and 3 trials moving their date back by more than 6 months. F13
  • The DataCutoff timing model estimates this trial finishes about 2 months after its registry date, and up to 8 months in slower cases, but the registry gives a primary completion date of 1 Dec 2026. F9 F11

Filings

  • The company has $62M in cash and short-term investments, which is expected to last about 5 months, covering the primary completion date of the trial. F14 F15
  • The company has reported an FDA decision date of 12 Dec 2026, which is after the estimated primary completion date of the trial. F17

The case for

  • The trial's design features, including quadruple blinding and randomised allocation, will help to reduce bias and increase the reliability of the results, which will be based on the proportion of participants with at least 1 vomiting episode per week in the tradipitant group compared to the placebo group. F3 F4 F5
  • The company has a record of keeping dates, with only 8% of their active Phase 2 and 3 trials moving their date back by more than 6 months, and the registry gives a primary completion date of 1 Dec 2026, which has not moved later since the first registry version. F9 F10 F13

The case against

  • The trial's small size of 280 patients may limit the precision of the results, potentially leading to inconclusive or unreliable outcomes, which could contribute to a failed trial or delayed reporting. F2 F3 F6
  • Despite the company's history of keeping dates, there is still a possibility that the trial could be delayed, as 8% of VNDA's active Phase 2 and 3 trials have moved their date back by more than 6 months. F13
  • The DataCutoff timing model estimates that the trial could finish up to 8 months after its registry date in slower cases, which could lead to a delayed reporting of the results. F11

Open questions

  • Will the trial meet its primary completion date of 1 Dec 2026?
  • Will the results show a significant difference in the proportion of participants with at least 1 vomiting episode per week between the tradipitant and placebo groups?
  • Will the trial's outcome support a regulatory filing by VNDA?

6 AI sentences were removed by the fact check.

The facts

The trial

  • F1Tradipitant is a Phase 3 trial of Tradipitant in Nausea and Vomiting, sponsored by Vanda Pharmaceuticals (VNDA). source ↗
  • F2The trial plans to enrol 280 patients. source ↗

What counts as success

  • F3Main goal as written in the registry: Proportion of participants with at least 1 vomiting episode per week in the tradipitant group compared to the placebo group as measured by a daily symptom diary. source ↗
  • F4Blinding: quadruple blind. source ↗
  • F5Allocation: randomised. source ↗
  • F6The main goal is measured over: 1 week. source ↗
  • F7Number of study arms: 2. source ↗

When

  • F9The registry gives the primary completion date as 1 Dec 2026 (an estimate), which is 12 days from 19 Nov 2026. source ↗
  • F10The date has not moved later since the first registry version. source ↗
  • F11The DataCutoff timing model estimates this trial finishes about 2 months after its registry date, and up to 8 months in the slower quarter of cases. source ↗

Recruitment

Base rates

  • F12Historically 62.1% of Phase 3 programmes in cardiovascular and metabolic (the group DataCutoff files this trial under) moved on to a regulatory filing (BIO / Informa / QLS study of 2011 to 2020). This is an industry average, not a forecast for this trial.
  • F138% of VNDA's active Phase 2 and 3 trials have moved their date back by more than 6 months. source ↗

Money, insiders and FDA

  • F14VNDA reported $62M in cash and short-term investments as of 30 Sep 2026 (10-Q). source ↗
  • F15At the last 12 months' rate of spending (about $12M a month) that cash lasts about 5 months, to around Mar 2027, which is after the registry's primary completion date. source ↗
  • F16Insiders made 3 open-market purchases in the last 90 days, totalling $38K; the largest was $22K by the Director on 5 Nov 2026. source ↗
  • F17VNDA has reported an FDA decision date of 12 Dec 2026 in an SEC filing. source ↗

How this page is made: the facts come straight from the trial registry, SEC filings and FDA records, each with its link. AI analysts may only restate those facts, and any sentence with a number that is not in a cited fact is removed before publishing. How our models work. Dates are company-reported estimates. Information only, not investment or medical advice.